Il linfoma follicolare (FL) è una malattia del sistema linfatico, a partenza dai linfociti B, ed è caratterizzata da un decorso lento (si sviluppa nel corso di anni), per cui viene annoverata tra i linfomi indolenti.
Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelinesfor diagnosis, treatment and follow-up. Ann. Oncol. 27, v8–v90 (2016).
Carbone A, et al. Follicular lymphoma. Nat Rev Dis Pri - mers. 12;5(1):83 (2019).
Choi SM, et al. Follicular lymphoma diagnostic caveats and updates. Arch. Pathol. Lab. Med. 142, 1330–1340 (2018).
Jaffe ES, et al. in WHO Classification of Tumours of Hae - matopoietic and Lymphoid Tissues (Swerdlow, S. H. et al.) (IARC, 2017).
Carbone A, et al. The germinal centre-derived lympho - mas seen through their cellular microenvironment. Br. J. Haematol. 145, 468–480 (2009).
Randall C, Fedoriw Y. Pathology and diagnosis of follicu - lar lymphoma and related entities. Pathology. 52(1), pp. 30–39 (2020).
Sovani V, et al. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspi - rate and peripheral blood findings. J. Clin. Pathol. 67, 389–395 (2014).
Metser U, et al. Impact of 18F-FDG PET/CT on the staging and management of follicular lymphoma. Br J Radiol. Oct;87(1042):20140360 (2014).
Huet S, et al. From genetics to the clinic: a translatio - nal perspective on follicular lymphoma. Nat Rev Cancer. 18(4):224-239 (2018).
Morin RD, et al. Frequent mutation of histonemodifying ge - nes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
Yildiz M, et al. Activating STAT6 mutations in follicular lymphoma. Blood 125, 668–679 (2015).
Fend F, et al. Early lesions in lymphoid neoplasia: conclu - sions based on the Workshop of the XV Meeting of the Eu - ropean Association and the Society of Hematopathology, in Uppsala, Sweden. J. Hematop. 5, 169 (2012).
Jegalian AG, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 118, 2976–2984 (2011)
Goates JJ, et al. Floral variant of follicular lymphoma. Immunological and molecular studies support a neopla - stic process. Am. J. Surg. Pathol. 18, 37–47 (1994).
Nathwani BN, et al. Clinical significance of follicular lym - phoma with monocytoid B cells. Non-Hodgkin’s Lymphoma Classification Project. Hum. Pathol. 30, 263–268 (1999).
Agrawal R, Wang J. Pediatric follicular lymphoma: a rare clinicopathologic entity. Arch. Pathol. Lab. Med. 133, 142–146 (2009).
Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
Lones MA, et al. Primary follicular lymphoma of the te - stis in children and adolescents. J Pediatr Hematol Oncol. 34: 68–71 (2012).
Takata K, et al. Gastrointestinal follicular lymphoma: current knowledge and future challenges. Pathol Int. 68: 1–6 (2018)
Suárez AL, et al. Primary cutaneous B-cell lymphomas: Part I. Clinical features, diagnosis, and classification. J Am Acad Dermatol. 69: 329.e1–13 (2013)
AIOM. Linee guida linfomi. Edizione 2018.
23. Solal-Céligny P, et al. Follicular lymphoma international prognostic index. Blood 104, 1258–1265 (2004).
Federico M, et al. Follicular lymphoma international pro - gnostic index 2: a new prognostic index for follicular lym - phoma developed by the international follicular lympho - ma prognostic factor project. J Clin Oncol. 27(27):4555-62 (2009).
Pastore A, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immuno - chemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16(9):1111-1122 (2015).
Bachy E, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunoche - motherapy. Blood. 132(1):49-58 (2018).
Medeiros LJ, et al. in Tumors of the Lymph Nodes and Spleen. 205–238 (American Registry of Pathology, 2017).
.Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J. Clin. Oncol. 33, 2516–2522 (2015).
Friedberg JW, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J. Clin. Oncol. 27, 1202–1208 (2009).
Link BK, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J. Clin. Oncol. 31, 3272–3278 (2013).
Per altre richieste
la direzione medica.
Per informazioni o approfondimenti, è possibile contattare la Direzione Medica di Roche Italia